Pediatrix Medical Group (NYSE:MD) Issues Quarterly Earnings Results

Pediatrix Medical Group (NYSE:MD) announced its earnings results on Tuesday. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04, FiscalAI reports. The company had revenue of $487.78 million for the quarter, compared to the consensus estimate of $478.49 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The company’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.53 EPS.

Here are the key takeaways from Pediatrix Medical Group’s conference call:

• Q2 adjusted EBITDA was $76 million, and management reaffirmed its 2026 adjusted EBITDA outlook of $280 million–$300 million.
• Consolidated revenue increased 4%, with same-unit revenue up 2% as stronger RCM collections, favorable payer mix, and higher patient acuity more than offset lower volumes.
• Same-unit patient service volumes declined 2%, including a 3% decrease in NICU days; management expects full-year volume to be flat to slightly down and said RCM collection benefits will begin to fade in the second half.
• The company repurchased nearly 2 million shares during the quarter, bringing total buybacks since August 2025 to 7 million shares and reducing shares outstanding to 81 million.
• Pediatrix is pursuing growth through tele-hybrid services, obstetric hospitalist programs, acquisitions, and potential joint ventures in women’s and children’s healthcare, while emphasizing disciplined financial and operating returns.

Pediatrix Medical Group Stock Up 1.5%

NYSE MD traded up $0.39 during trading on Thursday, hitting $26.38. 76,293 shares of the company traded hands, compared to its average volume of 801,040. Pediatrix Medical Group has a 12 month low of $14.04 and a 12 month high of $27.94. The business has a fifty day simple moving average of $24.85 and a 200 day simple moving average of $22.56. The company has a market capitalization of $2.17 billion, a P/E ratio of 12.54 and a beta of 0.66. The company has a current ratio of 2.19, a quick ratio of 1.33 and a debt-to-equity ratio of 0.66.

Insider Activity

In other news, Director Shirley A. Weis sold 36,028 shares of the stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total transaction of $855,665.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Pediatrix Medical Group by 5.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,569,219 shares of the company’s stock worth $76,349,000 after buying an additional 169,441 shares during the period. Geode Capital Management LLC lifted its position in Pediatrix Medical Group by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 2,181,712 shares of the company’s stock worth $46,674,000 after acquiring an additional 14,421 shares during the last quarter. Boston Partners lifted its position in Pediatrix Medical Group by 0.6% during the 3rd quarter. Boston Partners now owns 1,427,953 shares of the company’s stock worth $24,063,000 after acquiring an additional 8,335 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Pediatrix Medical Group by 4.0% during the fourth quarter. Renaissance Technologies LLC now owns 1,357,700 shares of the company’s stock valued at $29,041,000 after acquiring an additional 51,700 shares during the period. Finally, Qube Research & Technologies Ltd boosted its holdings in Pediatrix Medical Group by 55.4% during the third quarter. Qube Research & Technologies Ltd now owns 1,143,306 shares of the company’s stock valued at $19,150,000 after acquiring an additional 407,780 shares during the period. Institutional investors own 97.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MD. Mizuho set a $24.00 price target on Pediatrix Medical Group in a research report on Friday, May 8th. Truist Financial lifted their target price on Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pediatrix Medical Group in a report on Thursday. Weiss Ratings raised shares of Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $25.00 price target on shares of Pediatrix Medical Group in a report on Wednesday. Two analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $24.83.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.